Center for Clinical Pathology, Capital Medical University, Beijing 100069, P.R. China.
Oncol Rep. 2013 Dec;30(6):2741-8. doi: 10.3892/or.2013.2769. Epub 2013 Oct 1.
Decoy receptor 3 (DcR3) is considered to have anti‑apoptotic and pro-metastatic functions, suggesting it might be a therapeutic target. We examined the role and mechanisms of DcR3 on growth and the metastatic ability of SW480 colon cancer cells to provide therapeutic information for targeting DcR3 by RNA interference (RNAi) technology. Growth and the metastatic ability were inhibited, apoptosis was induced and cell cycle profile was changed after decreasing DcR3 expression, with lower levels of vascular endothelial growth factors (VEGFs) and matrix metalloproteinases (MMPs) expression. Our results implied the therapeutic potential of silencing DcR3 expression by RNAi in colon cancer.
诱饵受体 3(DcR3)被认为具有抗凋亡和促转移的功能,提示它可能是一个治疗靶点。我们研究了 DcR3 在 SW480 结肠癌细胞生长和转移能力中的作用和机制,为通过 RNA 干扰(RNAi)技术靶向 DcR3 提供治疗信息。降低 DcR3 表达后,抑制生长和转移能力,诱导细胞凋亡,改变细胞周期谱,降低血管内皮生长因子(VEGFs)和基质金属蛋白酶(MMPs)的表达水平。我们的研究结果表明,通过 RNAi 沉默 DcR3 表达在结肠癌中具有治疗潜力。